News

Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.

Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.

“We used to think that aging-related memory and thinking decline meant one thing: a disease called Alzheimer’s disease. Now we know that the disease we were calling Alzheimer’s disease is actually many different conditions, often in combination."

Prendergast says statistics show that less than five percent of undergraduate neuroscience students in the U.S. are Black or African American, but at UK nearly ten percent of undergraduate neuroscience majors identify as Black or African American.

Researchers will be looking at a medication that recently received experimental approval from the USDA and its impact on the newly characterized form of dementia known as LATE. LATE is a disease with symptoms similar to Alzheimer’s disease.

The National Institutes of Health award will fund ongoing research led by UK Neuroscience and Spinal Cord and Brain Injury Research Center (SCoBIRC) Professor Patrick Sullivan, Ph.D., who has studied the effects of the experimental drug MP201 on TBI.

The work at UK in Gentry’s lab supported by this award will focus on novel insights in energy metabolism using cutting edge methodologies applied to multiple human diseases.

Linda J. Van Eldik, director of the Sanders-Brown Center on Aging at UK, co-authored a paper reporting the first human clinical study of a drug candidate that suppresses injury and disease-induced inflammation of the brain.

When you look back at a 45-year career, there are a multitude of moments that stand out. For Allan Butterfield, Professor of Biological Chemistry in the UK College of Arts & Sciences, his signature discovery grew from just such a Eureka moment on the sidewalk on campus. 

“I can’t advocate for someone unless I’m working with them. It’s presumptuous to say, ‘I know what you need,’” Kitzman said. “The moment we at KARRN start working with someone, we agree to be their advocate and do whatever it takes to find resources for them.”